[Effects of radiotherapy on plasma T 1/2 59Fe in patients with lung cancer and lymphomas].
The variations of the plasma 59Fe T 1/2 were observed in 20 patients treated by high-energy irradiation. They were submitted to a focalized radiotherapy involving a non-negligible volume of erythropoietic marrow. Among them there were 10 cases of pulmonary cancer, 7 cases of lymphomas, and 3 cases of seminomas. When treatment was limited to an irradiation of the thorax, no significant change of the 59Fe T 1/2 was observed in cases of pulmonary cancer or lymphomas. In case of a supra and infradiaphragmatic irradiation (lymphomas), the 59Fe T 1/2 (initially subnormal) tended to reach normal values after radiotherapy and seems to be independent of the initial value (before irradiation) and of the delivered dose.
D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D004407:Dysgerminoma / Q000532:radiotherapy; D004920:Erythropoiesis / Q000528:radiation effects*; D005260:Female; D006207:Half-Life; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007504:Iron Radioisotopes; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008223:Lymphoma / Q000532:radiotherapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy; D008297:Male; D011830:Radiation Effects; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D013736:Testicular Neoplasms / Q000532:radiotherapy
D003037:Cobalt Radioisotopes; D007504:Iron Radioisotopes; D007501:Iron
Effets du traitement radiothérapique sur le T 1/2 59fe plasmatique dans les cancers pulmonaires et les lymphomes